AID Genomics is an international group of medical technology companies specializing in the diagnosis and therapy of cancer. In 2017, the company acquired GeneSort, a diagnostics company that develops and performs genomic and genetic testing for an accurate and personalized cancer care.
AID Genomics advanced testing platforms are developed by a leading team of experts in the fields of oncology, molecular biology, molecular pathology, genomics and bioinformatics.
AID Genomics uses cutting edge technology to substantially improve cancer patients' survival rate and quality of life by offering early detection process integrated with personalized preventive medicine.
To continuously expand our knowledge and capabilities in order to provide the most efficient and effective products and services for cancer prevention, detection, treatment and monitoring.
Founder, Chief Scientist (CSO)
Chairman of the board